uniQure Secures $259M from Upsized Public Offering, Underwriters Fully Exercise Option
QURE has more than doubled off its 52-week low of $8.73.
Summary
uniQure has successfully closed its upsized public offering, securing approximately $259 million in gross proceeds. The underwriters fully exercised their option to purchase additional shares, indicating strong demand. This financing follows the company's recent shareholder approval to increase authorized share capital and positive FDA guidance for its Huntington's disease gene therapy, AMT-130. The substantial capital infusion will fund commercialization activities for AMT-130, a confirmatory study, and further pipeline development. The company plans to submit a Biologic License Application for AMT-130 in Q3 2026.
At the time of this announcement, QURE was trading at $49.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $8.73 to $71.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.